Until recently, there has been no amyloid-targeting treatment available for Alzheimer's disease. We imagine a future where providers have the tools needed to identify, diagnose, select the right treatment, and monitor and visualize treatment response. A future where a strong provider network collaborates with patients and their families to identify signs of Alzheimer’s – even before symptoms begin.
We are here to instill hope in the face of Alzheimer's disease and to make this vision a reality.
Facts and Figures¹
Estimated number of Americans are living with Alzheimer’s Disease, which will likely grow to 12.7 M by 2050
leading cause of death in the United States
estimated hours of unpaid care provided by caregivers of people with Alzheimer’s Disease or other dementias
Projected in annual cost in the US driven by incurable, yet long-care timeline
Researchers continue to study how Alzheimer’s Disease changes the brain in the hope of identifying new treatments.
Tracer production is critical in PET imaging, with each tracer produced offering a potential step towards treatment.
Isotope (18F) tracer production providing a large supply or consistent, reliable, and cost-effective tracers.